[1]JournaloftheChemicalSociety.PerkintransactionsI,1997,p.185-186
[2]JournalofMedicinalChemistry,2000,vol.43,p.2797-2804
[1]JournalofMedicinalChemistry,2000,vol.43,p.4071-4083
[2]BioorganicandMedicinalChemistry,2013,vol.21,p.1685-1695
[3]MedicinalChemistry,2017,vol.13,p.28-39
[1]Journalofmedicinalchemistry,2004,vol.47,p.3710-3722
[1]Journalofmedicinalchemistry,2004,vol.47,p.3710-3722
[1]Journalofmedicinalchemistry,2004,vol.47,p.3710-3722
Title: 6-Oxo and 6-thio purine analogs as antimycobacterial agents.
Journal: Bioorganic & medicinal chemistry 20130401
Title: The kinase inhibitor O6-cyclohexylmethylguanine (NU2058) potentiates the cytotoxicity of cisplatin by mechanisms that are independent of its effect upon CDK2.
Journal: Biochemical pharmacology 20090515
Title: Identifying tumor cell growth inhibitors by combinatorial chemistry and zebrafish assays.
Journal: PloS one 20090101
Title: Regiospecific microwave-assisted synthesis and cytotoxic activity against human breast cancer cells of (RS)-6-substituted-7- or 9-(2,3-dihydro-5H-1,4-benzodioxepin-3-yl)-7H- or -9H-purines.
Journal: European journal of medicinal chemistry 20080801
Title: EmbR2, a structural homologue of EmbR, inhibits the Mycobacterium tuberculosis kinase/substrate pair PknH/EmbR.
Journal: The Biochemical journal 20080301
Title: Therapeutic potential of CDK inhibitor NU2058 in androgen-independent prostate cancer.
Journal: Oncogene 20071206
Title: Novel structural features of CDK inhibition revealed by an ab initio computational method combined with dynamic simulations.
Journal: Journal of medicinal chemistry 20060824
Title: Searching for cyclin-dependent kinase inhibitors using a new variant of the cope elimination.
Journal: Journal of the American Chemical Society 20060510
Title: Microsphere-based protease assays and screening application for lethal factor and factor Xa.
Journal: Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501
Title: N2-substituted O6-cyclohexylmethylguanine derivatives: potent inhibitors of cyclin-dependent kinases 1 and 2.
Journal: Journal of medicinal chemistry 20040715
Title: The development of a CDK2-docking site peptide that inhibits p53 and sensitizes cells to death.
Journal: Cell cycle (Georgetown, Tex.) 20040101
Title: Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor.
Journal: Nature structural biology 20021001
Title: Probing the ATP ribose-binding domain of cyclin-dependent kinases 1 and 2 with O(6)-substituted guanine derivatives.
Journal: Journal of medicinal chemistry 20020801
Title: Rigas AC, et al. Therapeutic potential of CDK inhibitor NU2058 in androgen-independent prostate cancer. Oncogene. 2007 Dec 6;26(55):7611-7619.